Under the agreement, 百时美施贵宝 will pay $50M upfront and near-term, with up to ~$800M in development, regulatory, and commercial milestones, plus tiered royalties. The collaboration centers on Janux Therapeutics tumor-activated T cell engager platform, which aims to address one of the biggest limitations of classic T cell engagers: systemic toxicity.
Janux's approach uses a masking strategy that keeps the CD3/CD28-binding portion of the molecule inactive in circulation. The mask is cleaved by tumor-associated proteases, activating the therapy only near the tumor and potentially reducing risks like cytokine release syndrome. If it works as intended, this could meaningfully widen the therapeutic window for T cell engagers in solid tumors. The target antigen hasn't been disclosed, other than being expressed across multiple solid tumor types. Janux Therapeutics will handle preclinical work and IND filing, with BMS taking over clinical development after Phase I.
Zooming out, this deal fits neatly into 百时美施贵宝's broader strategy. Over the past year, the company has doubled down on oncology and immune-based platforms, from its $1B+ collaboration with Harbour BioMed to access advanced antibody discovery models, to its $1.5B acquisition of Orbital Therapeutics to expand into RNA-enabled cell therapies. While many large pharmas have pulled back from cell therapy, 百时美施贵宝 appears to be leaning in selectively and with an eye toward differentiated technology.
This partnership underscores where the field is heading: not just more immune activation, but smarter, more localized immune engagement. If tumor-activated approaches can deliver efficacy without the usual toxicity tradeoffs, they could unlock a much broader role for T cell engagers in solid tumors.
Curious to see how this platform performs once it reaches the clinic.
百时美施贵宝 just struck another notable oncology deal, this time partnering with Janux Therapeutics to advance a next-generation T cell–based therapy designed to be active only in the tumor microenvironment.
#BCIC #Biotech #Tcells